Validation of 3‐ and 5‐point severity scales to assess ARIA‐E

Luc Bracoud(BioClinica (United States)), Joyce Suhy(BioClinica (United States)), Marco Lyons(Roche (United Kingdom)), Derk D. Purcell(BioClinica (United States)), Szofia Bullain(Roche (Switzerland)), Marzia A. Scelsi(Roche (United Kingdom)), Jakub Wojtowicz(Roche (Switzerland)), Jerome Barakos(Sutter Health), Jochen B. Fiebach(Pathodiagnostik Berlin), Gregory Klein(Roche (Switzerland))
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
October 1, 2023
10.1002/dad2.12503
Cited by 10

Related Papers

MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
|New England Journal of Medicine|2018|1.3k
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study
|The Lancet Neurology|2011|587